{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:38:10Z","timestamp":1790217490469,"version":"4.1.0"},"reference-count":76,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.<\/jats:p>","DOI":"10.3390\/jcm10163696","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T08:44:45Z","timestamp":1629449085000},"page":"3696","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives"],"prefix":"10.3390","volume":"10","author":[{"given":"Carlo","family":"Lavalle","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-7553","authenticated-orcid":false,"given":"Sara","family":"Trivigno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-0492","authenticated-orcid":false,"given":"Giampaolo","family":"Vetta","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9883-0114","authenticated-orcid":false,"given":"Michele","family":"Magnocavallo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-1209","authenticated-orcid":false,"given":"Marco Valerio","family":"Mariani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ospedale GB Grassi, 00121 Ostia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-8915","authenticated-orcid":false,"given":"Giovanni Battista","family":"Forleo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Ospedaliera-Universitaria \u201cLuigi Sacco\u201d, 20057 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ospedale Generale Regionale F. Miulli, Acquaviva delle Fonti, 70021 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Badagliacca","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Lanata","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Domp\u00e9 Farmaceutici SpA, 20057 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Pietro","family":"Ricci","sequence":"additional","affiliation":[{"name":"Centro Cardio-Aritmologico, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9149(84)90495-8","article-title":"Discovery and Development of Flecainide","volume":"53","author":"Hudak","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.65.5.879","article-title":"Suppression of Ventricular Ectopic Depolarizations by Flecainide Acetate, a New Antiarrhythmic Agent","volume":"65","author":"Hodges","year":"1982","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial Fibrillation Management: A Prospective Survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lavalle, C., Magnocavallo, M., Straito, M., Santini, L., Forleo, G.B., Grimaldi, M., Badagliacca, R., Lanata, L., and Ricci, R.P. (2021). Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071456"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9149(96)00673-X","article-title":"Impact of the Food and Drug Administration Approval of Flecainide and Encainide on Coronary Artery Disease Mortality: Putting \u201cDeadly Medicine\u201d to the Test","volume":"79","author":"Anderson","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9149(02)03008-4","article-title":"Outpatient Prescribing of Antiarrhythmic Drugs from 1995 to 2000","volume":"91","author":"LaPointe","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","article-title":"Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo","volume":"124","author":"Ruzieh","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.hrthm.2021.02.010","article-title":"Catheter Ablation of Ventricular Tachycardia in Ischemic Cardiomyopathy: Impact of Concomitant Amiodarone Therapy on Short- and Long-Term Clinical Outcomes","volume":"18","author":"Romero","year":"2021","journal-title":"Heart Rhythm"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hrthm.2017.12.018","article-title":"Class IC Antiarrhythmic Drugs for Suspected Premature Ventricular Contraction\u2013Induced Cardiomyopathy","volume":"15","author":"Hyman","year":"2018","journal-title":"Heart Rhythm"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hrthm.2016.12.010","article-title":"Use of Flecainide in Combination Antiarrhythmic Therapy in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"14","author":"Ermakov","year":"2017","journal-title":"Heart Rhythm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/pace.12250","article-title":"Combination Drug Therapy for Patients with Intractable Ventricular Tachycardia Associated with Right Ventricular Cardiomyopathy","volume":"37","author":"Ermakov","year":"2014","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CRD.0000000000000040","article-title":"Novel Perspectives on Arrhythmia-Induced Cardiomyopathy: Pathophysiology, Clinical Manifestations and an Update on Invasive Management Strategies","volume":"23","author":"Santini","year":"2015","journal-title":"Cardiol. Rev."},{"key":"ref_15","first-page":"e272","article-title":"2017 AHA\/ACC\/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"138","author":"Stevenson","year":"2018","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccep.2016.10.013","article-title":"Ventricular Tachycardia in Ischemic Heart Disease","volume":"9","author":"Lo","year":"2017","journal-title":"Card. Electrophysiol. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tcm.2018.09.014","article-title":"Treatment of Ventricular Arrhythmias: What\u2019s New?","volume":"29","author":"Markman","year":"2019","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jcph.679","article-title":"Arrhythmias Seen in Baseline 24-Hour Holter ECG Recordings in Healthy Normal Volunteers During Phase 1 Clinical Trials","volume":"56","author":"Hingorani","year":"2016","journal-title":"J. Clin. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacep.2015.04.005","article-title":"Multicenter Outcomes for Catheter Ablation of Idiopathic Premature Ventricular Complexes","volume":"1","author":"Latchamsetty","year":"2015","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/01.CIR.79.2.256","article-title":"Sustained Bundle Branch Reentry as a Mechanism of Clinical Tachycardia","volume":"79","author":"Caceres","year":"1989","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bhatt, A.G., and Mittal, S. (2018). Ventricular Tachycardia in Structurally Normal Hearts. Encyclopedia of Cardiovascular Research and Medicine, Elsevier.","DOI":"10.1016\/B978-0-12-809657-4.99777-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0733-8651(18)30347-3","article-title":"Cellular Electrophysiologic Mechanisms of Cardiac Arrhythmias","volume":"8","author":"Wit","year":"1990","journal-title":"Cardiol. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0733-8651(05)70360-X","article-title":"Cellular Electrophysiologic Mechanisms of Cardiac Arrhythmias","volume":"15","author":"Cabo","year":"1997","journal-title":"Cardiol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0095-4543(05)70170-6","article-title":"Ventricular Arrhythmias","volume":"27","author":"Flinders","year":"2000","journal-title":"Prim. Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.mcna.2019.05.008","article-title":"Ventricular Arrhythmias","volume":"103","author":"AlMahameed","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jce.12510","article-title":"Mechanism-Specific Effects of Adenosine on Ventricular Tachycardia","volume":"25","author":"Lerman","year":"2014","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.hrthm.2015.07.030","article-title":"A Swine Model of Infarct-Related Reentrant Ventricular Tachycardia: Electroanatomic, Magnetic Resonance, and Histopathological Characterization","volume":"13","author":"Tschabrunn","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4070\/kcj.2019.0292","article-title":"Ventricular Tachycardia Ablation in Non-Ischemic Cardiomyopathy","volume":"50","author":"Bhaskaran","year":"2020","journal-title":"Korean Circ. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10840-019-00617-9","article-title":"Electrocardiographic Features, Mapping and Ablation of Idiopathic Outflow Tract Ventricular Arrhythmias","volume":"57","author":"Lavalle","year":"2020","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1540-8159.2012.03488.x","article-title":"Using the Surface Electrocardiogram to Localize the Origin of Idiopathic Ventricular Tachycardia","volume":"35","author":"Park","year":"2012","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccep.2018.02.006","article-title":"Localization of Ventricular Arrhythmias for Catheter Ablation: The Role of Surface Electrocardiogram","volume":"10","author":"Gianni","year":"2018","journal-title":"Card. Electrophysiol. Clin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.hrthm.2018.11.028","article-title":"Variant of Ventricular Outflow Tract Ventricular Arrhythmias Requiring Ablation from Multiple Sites: Intramural Origin","volume":"16","author":"Romero","year":"2019","journal-title":"Heart Rhythm"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.jacc.2011.01.035","article-title":"The V(2) Transition Ratio: A New Electrocardiographic Criterion for Distinguishing Left from Right Ventricular Outflow Tract Tachycardia Origin","volume":"57","author":"Betensky","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.hrthm.2019.09.021","article-title":"Simple Electrocardiographic Criteria for Rapid Identification of Wide QRS Complex Tachycardia: The New Limb Lead Algorithm","volume":"17","author":"Chen","year":"2020","journal-title":"Heart Rhythm"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1016\/j.jacc.2017.10.030","article-title":"Catheter Ablation of Ventricular Tachycardia in Structural Heart Disease: Indications, Strategies, and Outcomes-Part II","volume":"70","author":"Dukkipati","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jacep.2017.07.011","article-title":"Cellular Physiology and Clinical Manifestations of Fascicular Arrhythmias in Normal Hearts","volume":"3","author":"Sung","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jce.12020","article-title":"Diagnosis and Ablation of Multiform Fascicular Tachycardia","volume":"24","author":"Sung","year":"2013","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0002-9149(84)90510-1","article-title":"Effects of Flecainide on Ventricular Function: Clinical and Experimental Correlations","volume":"53","author":"Josephson","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.RES.66.3.789","article-title":"Interactions of Flecainide with Guinea Pig Cardiac Sodium Channels. Importance of Activation Unblocking to the Voltage Dependence of Recovery","volume":"66","author":"Anno","year":"1990","journal-title":"Circ. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/01.CIR.82.1.289","article-title":"Block of Delayed Rectifier Potassium Current, IK, by Flecainide and E-4031 in Cat Ventricular Myocytes","volume":"82","author":"Follmer","year":"1990","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hrthm.2015.09.027","article-title":"Flecainide Monotherapy Is an Option for Selected Patients with Catecholaminergic Polymorphic Ventricular Tachycardia Intolerant of \u03b2-Blockade","volume":"13","author":"Padfield","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yjmcc.2009.10.005","article-title":"Flecainide Inhibits Arrhythmogenic Ca2+ Waves by Open State Block of Ryanodine Receptor Ca2+ Release Channels and Reduction of Ca2+ Spark Mass","volume":"48","author":"Hilliard","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.hrthm.2014.11.009","article-title":"Cardiac Late Na+ Current: Proarrhythmic Effects, Roles in Long QT Syndromes, and Pathological Relationship to CaMKII and Oxidative Stress","volume":"12","author":"Belardinelli","year":"2015","journal-title":"Heart Rhythm"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198529010-00001","article-title":"A Preliminary Review of Its Pharmacodynamic Properties and Therapeutic efficiancy","volume":"29","author":"Holmes","year":"1985","journal-title":"Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJM198607033150106","article-title":"Drug Therapy. Flecainide","volume":"315","author":"Roden","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0002-9149(88)90282-2","article-title":"Supraventricular Tachycardia Mimicking Ventricular Tachycardia during Flecainide Treatment","volume":"62","author":"Crijns","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2165\/00003495-200464240-00003","article-title":"Pharmacological Cardioversion of Atrial Fibrillation: Current Management and Treatment Options","volume":"64","author":"Boriani","year":"2004","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9149(84)90511-3","article-title":"Extracardiac Adverse Effects of Flecainide","volume":"53","author":"Gentzkow","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9149(84)90501-0","article-title":"Metabolism of Flecainide","volume":"53","author":"Conard","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2125.1986.tb02892.x","article-title":"Flecainide: Single and Multiple Oral Dose Kinetics, Absolute Bioavailability and Effect of Food and Antacid in Man","volume":"22","author":"Verbesselt","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/FPC.0b013e328361fb8d","article-title":"SCN5A Promoter Haplotype Affects the Therapeutic Range for Serum Flecainide Concentration in Asian Patients","volume":"23","author":"Doki","year":"2013","journal-title":"Pharm. Genom."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-Five Years in the Making: Flecainide Is Safe and Effective for the Management of Atrial Fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"Europace"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11599950-000000000-00000","article-title":"Safety of Flecainide","volume":"35","author":"Tamargo","year":"2012","journal-title":"Drug Saf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0735-1097(86)80234-0","article-title":"Flecainide and Amiodarone Interaction","volume":"7","author":"Shea","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_56","unstructured":"Meda Pharmaceuticals Ltd. (2014, August 17). Flecainide Acetate\u2014Summary of Product Characteristics (UK). Available online: www.Medicines.Org.Uk\/Emc\/Medicine\/3905."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2125.2008.03267.x","article-title":"Pharmacokinetic Interaction of Flecainide and Paroxetine in Relation to the CYP2D6*10 Allele in Healthy Korean Subjects","volume":"66","author":"Lim","year":"2008","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1176\/ajp.153.3.311","article-title":"Newer Antidepressants and the Cytochrome P450 System","volume":"153","author":"Nemeroff","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00005344-200305000-00015","article-title":"Pharmacodynamic Equivalence of Two Flecainide Acetate Formulations in Patients with Paroxysmal Atrial Fibrillation by QRS Analysis of Ambulatory Electrocardiogram","volume":"41","author":"Coumel","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tarantino, N., Della Rocca, D., De Leon De La Cruz, N., Manheimer, E., Magnocavallo, M., Lavalle, C., Gianni, C., Mohanty, S., Trivedi, C., and Al-Ahmad, A. (2021). Catheter Ablation of Life-Threatening Ventricular Arrhythmias in Athletes. Medicina, 57.","DOI":"10.3390\/medicina57030205"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.hrthm.2013.08.011","article-title":"Flecainide Therapy Suppresses Exercise-Induced Ventricular Arrhythmias in Patients with CASQ2-Associated Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"10","author":"Khoury","year":"2013","journal-title":"Heart Rhythm"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.hrthm.2012.12.035","article-title":"Effects of Flecainide on Exercise-Induced Ventricular Arrhythmias and Recurrences in Genotype-Negative Patients with Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"10","author":"Watanabe","year":"2013","journal-title":"Heart Rhythm"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.recesp.2017.04.014","article-title":"Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-Positive Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"71","year":"2018","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fphys.2019.00992","article-title":"Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload","volume":"10","author":"Hwang","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_66","first-page":"370","article-title":"Long-Term Flecainide Therapy in Type 3 Long QT Syndrome","volume":"20","author":"Chorin","year":"2018","journal-title":"EP Eur."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.hrthm.2014.12.009","article-title":"Efficacy and Safety of Flecainide for Ventricular Arrhythmias in Patients with Andersen-Tawil Syndrome with KCNJ2 Mutations","volume":"12","author":"Miyamoto","year":"2015","journal-title":"Heart Rhythm"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Natale, A., and Jalife, J. (2008). Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation. Atrial Fibrillation, Humana Press.","DOI":"10.1007\/978-1-59745-163-5"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0002-9149(91)90308-8","article-title":"The CAST Investigators Increased Risk of Death and Cardiac Arrest from Encainide and Flecainide in Patients after Non-Q-Wave Acute Myocardial Infarction in the Cardiac Arrhythmia Suppression Trial","volume":"68","author":"Akiyama","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0002-9149(02)02867-9","article-title":"Efficacy and Safety of Propafenone Sustained Release in the Prophylaxis of Symptomatic Paroxysmal Atrial Fibrillation (The European Rythmol\/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study)","volume":"90","author":"Meinertz","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jce.14335","article-title":"Class 1C Antiarrhythmic Drugs in Atrial Fibrillation and Coronary Artery Disease","volume":"31","author":"Pantlin","year":"2020","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ashraf, H., Ko, N.K., Ladia, V., Agasthi, P., Prendiville, T., O\u2019Herlihy, F., Pujari, S.H., Mulpuru, S.K., Scott, L., and Sorajja, D. (2021). Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery Disease. Am. J. Cardiovasc. Drugs, 1\u201310.","DOI":"10.1007\/s40256-021-00483-9"},{"key":"ref_73","first-page":"209","article-title":"Management of Ventricular Tachycardia in the Ablation Era: Results of the European Heart Rhythm Association Survey","volume":"20","author":"Tilz","year":"2018","journal-title":"EP Eur."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/pace.12426","article-title":"Left Ventricular Hypertrophy and Antiarrhythmic Drugs in Atrial Fibrillation: Impact on Mortality: LVH, Antiarrhythmic Drugs, and Mortality","volume":"37","author":"Chung","year":"2014","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00380-014-0534-3","article-title":"Effects of Flecainide on Left Ventricular Pressure Gradient and Symptoms in Obstructive Hypertrophic Cardiomyopathy: A Comparison of Flecainide and Disopyramide","volume":"30","author":"Haruki","year":"2015","journal-title":"Heart Vessel."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jcmg.2019.04.023","article-title":"CMR for Identifying the Substrate of Ventricular Arrhythmia in Patients With Normal Echocardiography","volume":"13","author":"Andreini","year":"2020","journal-title":"JACC Cardiovasc. Imaging"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3696\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:48:00Z","timestamp":1760165280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":76,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jcm10163696"],"URL":"https:\/\/doi.org\/10.3390\/jcm10163696","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}